Psoriasis treatment

Gáspár, Krisztián Absztrakt: Psoriasis is a papulosquamous chronic skin disease that requires life-long management.

Ixekizumab IXE is a high-affinity selective monoclonal antibody against interleukin IL A which is registered treating moderate-to-severe plaque psoriasis. The purpose of this thesis work is to assess the outcomes of patients who interrupted the treatment and were subsequently retreated with IXE, as well as Többet Psoriasis is a papulosquamous chronic skin disease that requires life-long management.

The purpose of this thesis work is to assess the outcomes of patients who interrupted the treatment and were subsequently retreated with IXE, as well as to investigate if after the temporary suspension the psoriasis treatment will ever psoriasis treatment able to reach again their best clinical score obtained before.

Information was collected from patients available in the Department of Dermatology, in the University of Debrecen.

The investigation was authorized by the Local Ethics Committee H. The patients started the normal regimen of IXE, after induction, receiving 80 mg every 4 weeks until the treatment was stopped.

After that, further financial support was requested from responsible bureaus for the treatment continuation.

Waiting upon approval patients were suspended an average of 94 days until re-start was realized. IXE demonstrated to be highly effective in the clearance of psoriatic skin even after the treatment was interrupted taking a relatively short time to regain efficacy and with no encountered clinically significant side effects.

The PRESTA Psoriasis Randomized Etanercept STudy in Patients with Psoriatic Arthritis study, a randomized, double-blind, two-dose trial, examined the efficacy of etanercept treatment in patients with moderate-to-severe plaque psoriasis and PsA and the main results have been presented previously. This analysis examined employment status, job duties and sick days, pre-defined endpoints in PRESTA, among this patient population. All participants then received open-label etanercept 50 mg QW for 12 additional weeks, while remaining blinded to the randomization.